Form 4: BioLife Solutions Exec Sells Shares for Tax Obligations

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 509 shares of common stock for $27.36 each to cover tax withholding obligations.

Summary

• Aby J. Mathew, Executive Vice President & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 509 shares of common stock at a price of $27.36 per share.
• The sale occurred on October 9, 2025, and was executed under a Rule 10b5-1(c) trading plan.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following this transaction, Aby J. Mathew directly beneficially owns 350,912 shares of BioLife Solutions common stock.
• The Rule 10b5-1(c) trading plan was adopted effective January 3, 2023.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale for tax withholding purposes, which is generally considered neutral in terms of market sentiment as it does not reflect a discretionary decision based on new information about the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of a small portion of an executive's holdings to cover tax obligations associated with restricted stock vesting. Such transactions, especially when conducted under a Rule 10b5-1 plan, are not typically indicative of a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

BioLife Solutions, BLFS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Rule 10b5-1, Aby J. Mathew